SecBot SecBot
6-K ·Filed Jul 31, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001654954-26-007050
Notable filing: 6-K
Actionable Insight ▲ Bullish

The EU approval adds a significant label expansion for Datroway, supporting AstraZeneca's oncology revenue growth. Monitor upcoming sales reports and label expansions in additional geographies (China, Japan) for further upside. The strong OS and PFS data may also support future guideline inclusion and pricing negotiations.

DirectionBullish
Confidencehigh
Horizonweeks

Drug in focus

AZN drug pipeline →

Datroway

▲ Bullish Named in this 6-K
Impact
Phase
Approved
Time to market
Already approved and marketed (first US approval Jan 2025, three indications now approved)
Next catalyst
None dated

What to watchWatch AstraZeneca's quarterly earnings for Datroway sales growth as a commercial read-through. The ongoing TROPION-Lung trials (first-line NSCLC) could expand the addressable market materially if positive, but those readouts have no firm dates yet. The main competitive risk is Gilead's Trodelvy, but Datroway appears to have an efficacy and dosing edge.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$169.64
T+0 close · Jul 31, 2026 · via day close
Latest settled
+1.43%
T+60 · $172.06
Vs SPY
−1.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 31 $169.64entry
  2. T+1 · 4mo ago −6.90%α −8.32% · $157.93
  3. T+5 · 3mo ago −4.88%α −8.39% · $161.37
  4. T+20 · 3mo ago −4.12%α −7.10% · $162.66
  5. T+60 · 22d ago +1.43%α −1.03% · $172.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca's Datroway (datopotamab deruxtecan) received EU approval as monotherapy for 1st-line metastatic triple-negative breast cancer (TNBC) in patients ineligible for immunotherapy, based on the TROPION-Breast02 Phase III trial showing a 5.0-month median overall survival improvement (23.7 vs 18.7 months, HR 0.79) and a 43% reduction in progression/death risk. This expands Datroway's EU label to two breast cancer indications and positions it as the only TROP2-directed ADC with an overall survival benefit in this setting, reinforcing AstraZeneca's oncology growth trajectory.

Key Facts

  • EU approval for 1st-line metastatic TNBC in patients not candidates for PD-1/PD-L1 inhibitor therapy.
  • Approval based on TROPION-Breast02 Phase III trial: median OS 23.7 months (Datroway) vs 18.7 months (chemotherapy); HR 0.79 (p=0.0291).
  • Risk of disease progression or death reduced by 43% (HR 0.57; p<0.0001); ORR 62.5% vs 29.3%.
  • Datroway now approved for two breast cancer indications in the EU (HR+/HER2- and TNBC).
  • Previously approved in the US for same TNBC indication (May 2026); additional reviews ongoing in China, Japan, Australia, Canada, Singapore, Switzerland.
  • Included in ESMO Clinical Practice Guidelines as Category IA 1st-line option; ESMO-MCBS score 4/5.

Financial Impact

EU approval expands addressable market for Datroway in TNBC, a disease with ~81,000 annual diagnoses in Europe. No specific revenue figures provided in the filing.

revenuemarket share

Risk Factors

  • Competition from other TROP2-directed ADCs (e.g., Trodelvy) and emerging therapies in TNBC.
  • Reimbursement and pricing negotiations across EU member states may limit commercial uptake.
  • Continued approval in US for NSCLC indication contingent on confirmatory trial verification.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-007050
Document: 0001654954-26-007050-index-headers.html0001654954-26-007050
Document: 0001654954-26-007050-index.html0001654954-26-007050
Document: 0001654954-26-007050.txt0001654954-26-007050

Track record

77 reports on AZN

Performance horizon

19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 31, 2026